Magellanic Cloud readies drone facility with US$16 million plan
Key highlights
- MCL committed US$16 million of capex and opex under the Rayonix agreement dated 25 April 2026.
- Mcray Xtend’s UAV facility premises were ready in November 2026.
- MCL approved up to Rs 20 crore of Mcray Xtend India CCDs on 13 November 2026.
- MCL’s drone segment generated Rs 1.70 crore of H1 FY27 revenue, up 12.0% year on year.
powered by IRIS

In November 2026, Magellanic Cloud (MCL) had premises ready for Mcray Xtend’s unmanned aerial vehicle (UAV) facility after a US$16 million capital expenditure (capex) and operating expenditure (opex) commitment under the 25 April 2026 Rayonix agreement; MCL’s Board approved up to Rs 20 crore of compulsorily convertible debentures (CCDs) on 13 November for technology transfer and manufacturing set-up.
Know Magellanic Cloud inside out
Results, valuation, peers and who's buying, in one view.
What has MCL committed to Mcray Xtend?
MCL has committed US$16 million in total capex and opex under the Rayonix agreement dated 25 April 2026. The presentation identifies this as the funding commitment linked to the collaboration, rather than reporting it as completed expenditure. That distinction means the disclosed figure sets the planned financial envelope for the drone initiative but does not state how much had been deployed by November 2026.
MCL’s Board also approved up to Rs 20 crore of CCDs of Mcray Xtend India on 13 November 2026. The stated purpose is technology transfer and manufacturing set-up. The presentation does not disclose the conversion terms, issue price, timing of drawdown or the proportion of the Rs 20 crore that had been subscribed at the time of the update.
The two figures cover different disclosed elements of the plan. The US$16 million figure is the aggregate capex and opex commitment under the Rayonix agreement, while the up-to-Rs 20 crore CCD approval is a Board-authorised instrument for the Mcray Xtend India technology-transfer and manufacturing programme. MCL does not provide an exchange rate or equate the two amounts in the presentation.
How is Mcray Xtend structured within MCL’s drone plans?
Mcray Xtend is a joint venture with Rayonix Tech in which MCL holds 60%, according to the presentation. The venture is collaborating with Israel-based XTEND to make tactical drone systems in India. This structure places Mcray Xtend alongside Scandron, the other named autonomous-systems business in MCL’s drone segment.
Scandron is focused on autonomous aerial systems for logistics, surveillance, defence and agriculture, and MCL held 92.11% at H1 FY27, or the first half of financial year 2027. That holding increased from 70.00% following the March 2026 rights issue. Mcray Xtend therefore has a lower disclosed MCL ownership percentage than Scandron, but it is the vehicle specifically associated with the XTEND collaboration, technology transfer and the new UAV manufacturing premises.
The two operations also point to different product applications. Scandron’s presentation describes heavy-lift delivery over difficult terrain, long-endurance vertical take-off and landing systems for persistent monitoring, and precision spraying and crop mapping. Mcray Xtend is described as a tactical-drone manufacturing initiative, with products associated with Israel-based XTEND technology and a Make in India positioning.
What is ready at the Mcray Xtend drone facility?
The Mcray Xtend UAV facility premises were ready in November 2026, and the presentation says they are ready to build drones on XTEND’s XOS platform. This is a manufacturing-preparation milestone, not a disclosed production-volume milestone. MCL does not provide the facility’s location, installed capacity, expected output, commissioning date or first delivery schedule.
The product names displayed for the XTEND-linked initiative are XTENDER, SCORPIO 500, SCORPIO 1000 and WOLVERINE. The presentation does not assign a production target, contract value or customer order to any of those platforms. The disclosed evidence therefore supports readiness of premises and a planned manufacturing route, rather than confirmed commercial production or revenue from the facility.
The November 2026 premises update followed the 25 April 2026 collaboration commitment by about seven months. The 13 November 2026 CCD approval adds a disclosed funding and technology-transfer mechanism after the premises became ready. Together, those dates show sequential preparation steps: an agreement commitment, site readiness and Board approval for a manufacturing-set-up instrument.
Got a follow-up? Ask IRIS
How does MCL’s existing drone business compare with the new facility plan?
MCL reported drone-segment revenue of Rs 1.70 crore in H1 FY27, up 12.0% year on year. This is the only disclosed drone revenue figure in the presentation and it is reported at the segment level, not separately for Scandron or Mcray Xtend. The increase shows that MCL already had drone-related revenue before the Mcray Xtend facility preparation, although the presentation does not identify its source products or customers.
The new facility plan is financially and operationally distinct from that H1 FY27 revenue measure. Revenue records sales in the first half, whereas the US$16 million commitment concerns future capex and opex under the Rayonix agreement, and the up-to-Rs 20 crore CCD approval concerns technology transfer and manufacturing set-up. MCL does not provide a forecast linking the planned facility to a particular revenue contribution or profitability target.
MCL’s H2 FY27 strategy, covering the second half of financial year 2027, lists building autonomous systems as its third priority. Management says it intends to scale up Scandron and Mcray Xtend and advance the defence collaboration with Rayonix. The stated priority places the facility preparation within the wider H2 FY27 operating plan, but the presentation does not disclose a signed defence order, a manufacturing timetable or a target number of systems.
What should readers monitor after the November 2026 approval?
Readers should monitor whether MCL discloses the actual issuance or subscription of the up-to-Rs 20 crore CCDs, the related conversion terms and the deployment of proceeds toward technology transfer and manufacturing. Those details would clarify how the 13 November 2026 Board approval progresses from authorisation to execution. The presentation presently identifies only the approval ceiling and stated purpose.
A second point is the move from premises readiness to measurable operating activity. MCL has named four XTEND-associated platforms and said that its premises are ready to build drones on the XOS platform, but it has not disclosed capacity, certification, production commencement or customer deliveries. Any update on those items would provide evidence of the next stage beyond the November 2026 facility milestone.
Conclusion
MCL has disclosed a defined sequence for Mcray Xtend: a US$16 million capex-and-opex commitment under the 25 April 2026 Rayonix agreement, ready UAV premises in November 2026, and Board approval for up to Rs 20 crore of CCDs on 13 November 2026. The company is pairing the new tactical-drone manufacturing effort with an existing drone segment that generated Rs 1.70 crore of H1 FY27 revenue, up 12.0% year on year.
The next disclosed strategic period is H2 FY27, when MCL says it plans to scale Scandron and Mcray Xtend and advance the Rayonix defence collaboration. The key unresolved matters are the CCD execution terms, the amount of funding actually deployed, the pace of technology transfer, facility capacity and whether the named XTEND platforms secure production orders or deliveries.


